Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218608 · ClinicalTrials.gov registry record · Phase 2
Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00218608: Completed Phase 2 study, sponsored by University of Arkansas.
NCT00218608 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218608, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
Cocaine is an extremely addictive stimulant drug that directly affects the brain. It is used in several different forms and can be snorted, smoked, or injected to achieve the desired effect. Cocaine users are at risk for many health problems, both directly and indirectly related to the effects of cocaine. Disulfiram, a drug used to treat chronic alcoholism, may be effective in reducing cocaine use. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone.
Primary Outcome
Urine toxicology screens were conducted thrice-weekly for 14 weeks.
Interventions
- DRUG Disulfiram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2001-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00218608 record still lists
NCT00218608 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 1 intervention - of which Disulfiram is the first listed.
NCT00218608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00218608 about?
NCT00218608 is a clinical study titled "Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone". Cocaine is an extremely addictive stimulant drug that directly affects the brain. It is used in several different forms and can be snorted, smoked, or injected to achieve the desired effect. Cocaine users are at risk for many health problems, both directly and indirectly related to the effects of co...
What is the current status of trial NCT00218608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2001-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00218608?
The interventions under investigation include: Disulfiram (DRUG).
Who is sponsoring clinical trial NCT00218608?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00218608's enrollment target sits among peer trials
158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia